BPC-157 is a peptide therapy gaining attention for its ability to support muscle growth and recovery
Additionally, these agents favorably impact cardiovascular risk factors, including reductions in blood pressure and body weight, further enhancing kidney protection [27,28]
Intramuscular (IM) B12 injections using hydroxocobalamin, the preferred licensed form in the UK are recommended when: Oral supplementation has failed to correct a documented deficiency The patient has difficulty adhering to daily oral regimens Serum B12 levels remain persistently low despite adequate oral dosing There is clinical evidence of neurological or haematological complications In line with BNF guidance, the standard IM regimen for confirmed deficiency without neurological involvement is a loading course of 1 mg hydroxocobalamin on alternate days for two weeks , followed by maintenance of 1 mg every three months
Compounded medications, including compounded semaglutide, are not FDA-approved and may be prescribed only when a licensed provider determines a clinically significant difference for an identified patient
Despite these findings, Melanotan II is not FDA-approved and should be regarded as a research-only peptide